Professor Thornton is mistaken in his assumption that this paper represents the climax of the SCOPE study. This study was carried out to evaluate the performance of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble Flt-1) factors to predict preterm pre-eclampsia in the first 3529 women recruited into the SCOPE study. As Professor Thornton points out, a prespecified aim of the SCOPE study is to develop predictive tests for pre-eclampsia (primary outcome) with a prespecified secondary outcome of early onset pre-eclampsia. The rationale for this particular case–cohort study was to determine, in nulliparous women, the performance of biomarkers recognised by other researchers[2, 3] to have predictive value for preterm pre-eclampsia (<37 weeks), while SCOPE continued to recruit to a sample size sufficient for the predefined endpoints including pre-eclampsia <34 weeks. As written clearly in the paper, the results presented ‘are likely to represent the highest achievable performance of these combinations in a nulliparous population and ongoing studies will aim to confirm these findings in the entire SCOPE cohort’. The SCOPE study recruitment is now complete and the cohort comprises 5690 women. A larger set of candidate biomarkers have been measured in samples from all women in the cohort (blinded to final diagnoses), and analysis against the original endpoints (including all pre-eclampsia, pre-eclampsia <34 weeks) has been undertaken. The SCOPE Consortium will shortly be submitting for publication manuscripts that report the analysis of single and multiple biomarkers, in combination with clinical risk factors, in order to evaluate their value in the prediction of pre-eclampsia.